{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:31:09Z","timestamp":1776832269955,"version":"3.51.2"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.canlet.2022.215721","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T02:24:22Z","timestamp":1651890262000},"page":"215721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Unity brings strength: Combination of CAR-T cell therapy and HSCT"],"prefix":"10.1016","volume":"549","author":[{"given":"RuiHao","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiaoQi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8548-2832","authenticated-orcid":false,"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2022.215721_bib1","author":"Liu"},{"key":"10.1016\/j.canlet.2022.215721_bib2","series-title":"Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736","author":"Stephens","year":"2016"},{"key":"10.1016\/j.canlet.2022.215721_bib3","series-title":"How I Treat Early-Relapsing Follicular Lymphoma","author":"Casulo","year":"2019"},{"key":"10.1016\/j.canlet.2022.215721_bib4","first-page":"1331","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New England journal of medicine","volume":"382","author":"Wang","year":"2020","journal-title":"Mass Medical Soc"},{"key":"10.1016\/j.canlet.2022.215721_bib5","first-page":"439","volume":"vol. 378","author":"Maude","year":"2018"},{"key":"10.1016\/j.canlet.2022.215721_bib6","first-page":"45","volume":"vol. 380","author":"Schuster","year":"2019"},{"key":"10.1016\/j.canlet.2022.215721_bib7","series-title":"End of Phase I Results of ZUMA-3, a Phase 1\/2 Study of KTE-X19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients (Pts) with Relapsed\/refractory (R\/R) Acute Lymphoblastic Leukemia (ALL)","author":"Shah","year":"2019"},{"key":"10.1016\/j.canlet.2022.215721_bib8","first-page":"2307","volume":"vol. 32","author":"Alcantara","year":"2018"},{"key":"10.1016\/j.canlet.2022.215721_bib9","author":"Mardiana"},{"key":"10.1016\/j.canlet.2022.215721_bib10","doi-asserted-by":"crossref","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Molecular Therapy - Oncolytics [Internet]. 2016 [cited 2021 Jul 29];3:16011. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2372770516300353.","DOI":"10.1038\/mto.2016.11"},{"key":"10.1016\/j.canlet.2022.215721_bib11","series-title":"Minimal Residual Disease Prior to Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: a Meta-Analysis","author":"Buckley","year":"2017"},{"key":"10.1016\/j.canlet.2022.215721_bib12","series-title":"Influence of Pre-transplant Minimal Residual Disease on Prognosis after Allo-SCT for Patients with Acute Lymphoblastic Leukemia: Systematic Review and Meta-Analysis","author":"Shen","year":"2018"},{"key":"10.1016\/j.canlet.2022.215721_bib13","author":"Ea"},{"key":"10.1016\/j.canlet.2022.215721_bib14","series-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","author":"Locke","year":"2021"},{"key":"10.1016\/j.canlet.2022.215721_bib15","doi-asserted-by":"crossref","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. Blood [Internet]. 2021 [cited 2022 Jan 18];138:LBA-6. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497121069949.","DOI":"10.1182\/blood-2021-155068"},{"key":"10.1016\/j.canlet.2022.215721_bib17","author":"Byrne"},{"key":"10.1016\/j.canlet.2022.215721_bib18","doi-asserted-by":"crossref","unstructured":"Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, de Lima M, et al. The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma Myeloma and Leukemia [Internet]. 2014 [cited 2020 Oct 25];14:319\u201326. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S2152265014000032.","DOI":"10.1016\/j.clml.2014.01.002"},{"key":"10.1016\/j.canlet.2022.215721_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.15086","article-title":"Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia","author":"Lovisa","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2022.215721_bib20","author":"Fabrizio"},{"key":"10.1016\/j.canlet.2022.215721_bib21","series-title":"Monoclonal Antibodies in Acute Lymphoblastic Leukemia","author":"Jabbour","year":"2015"},{"key":"10.1016\/j.canlet.2022.215721_bib22","series-title":"Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy","author":"Barz Leahy","year":"2019"},{"key":"10.1016\/j.canlet.2022.215721_bib23","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215721_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16339","article-title":"Chimeric antigen receptor T-cell therapy as a bridge to haematopoietic stem cell transplantation for refractory\/relapsed B-cell acute lymphoblastic leukemia","author":"Zhang","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2022.215721_bib25","series-title":"Efficacy and Safety of Anti-CD19 CAR T-Cell Therapy in 110 Patients with B-Cell Acute Lymphoblastic Leukemia with High-Risk Features","author":"Zhang","year":"2020"},{"key":"10.1016\/j.canlet.2022.215721_bib26","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215721_bib27","series-title":"Safety of Allogeneic Hematopoietic Cell Transplant in Adults after CD19-Targeted CAR T-Cell Therapy","author":"Shadman","year":"2019"},{"key":"10.1016\/j.canlet.2022.215721_bib28","author":"Wudhikarn"},{"key":"10.1016\/j.canlet.2022.215721_bib30","author":"Gauthier"},{"key":"10.1016\/j.canlet.2022.215721_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01160-9","article-title":"Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2022.215721_bib34","series-title":"CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can Be Overcome through Novel CAR Engineering","author":"Majzner","year":"2020"},{"key":"10.1016\/j.canlet.2022.215721_bib35","series-title":"The Impact of Individual Comorbidities on Non-relapse Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation","author":"Fein","year":"2018"},{"key":"10.1016\/j.canlet.2022.215721_bib36","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/CJI.0000000000000233","article-title":"Donor-derived CAR-T cells serve as a reduced-intensity conditioning regimen for haploidentical stem cell transplantation in treatment of relapsed\/refractory acute lymphoblastic leukemia: case report and review of the literature","volume":"41","author":"Zhang","year":"2018","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2022.215721_bib37","series-title":"Optimization of CRISPR-Cas9 Knock-Out of CD33 in Human Hematopoietic Stem\/Progenitor Cells for Allogeneic Transplantation in Patients with Acute Myeloid Leukemia","author":"Cummins","year":"2019"},{"key":"10.1016\/j.canlet.2022.215721_bib38","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01178-z","article-title":"CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity","author":"Shi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2022.215721_bib39","series-title":"CD19 CAR T Cells Following Autologous Transplantation in Poor-Risk Relapsed and Refractory B-Cell Non-hodgkin Lymphoma","author":"Sauter","year":"2019"},{"key":"10.1016\/j.canlet.2022.215721_bib40","series-title":"Anti-CD19 CAR T Cells with High-Dose Melphalan and Autologous Stem Cell Transplantation for Refractory Multiple Myeloma","author":"Garfall","year":"2018"},{"key":"10.1016\/j.canlet.2022.215721_bib41","series-title":"Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated with CD19-Chimeric Antigen Receptor T-Cell Therapy","author":"Shouval","year":"2022"},{"key":"10.1016\/j.canlet.2022.215721_bib42","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1002\/ctm2.176","article-title":"Long-term outcomes of relapsed\/refractory double-hit lymphoma (r\/r DHL) treated with CD19\/22 CAR T-cell cocktail therapy","volume":"10","author":"Wei","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.canlet.2022.215721_bib43","series-title":"Outcome of Aggressive B-Cell Lymphoma with TP53 Alterations Administered with CAR T-Cell Cocktail Alone or in Combination with ASCT","author":"Wei","year":"2022"},{"key":"10.1016\/j.canlet.2022.215721_bib44","author":"Garfall"},{"key":"10.1016\/j.canlet.2022.215721_bib45","series-title":"CD19 CAR T Cells Following Autologous Transplantation in Poor-Risk Relapsed and Refractory B-Cell Non-hodgkin Lymphoma","author":"Sauter","year":"2019"},{"key":"10.1016\/j.canlet.2022.215721_bib46","series-title":"Sequential CD19\/22 CAR T-Cell Immunotherapy Following Autologous Stem Cell Transplantation for Central Nervous System Lymphoma","author":"Wu","year":"2021"},{"key":"10.1016\/j.canlet.2022.215721_bib47","author":"Ying"},{"key":"10.1016\/j.canlet.2022.215721_bib48","series-title":"Combined CD28 and 4-1BB Costimulation Potentiates Affinity-Tuned Chimeric Antigen Receptor\u2013Engineered T Cells","author":"Drent","year":"2019"},{"key":"10.1016\/j.canlet.2022.215721_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2022.215721_bib50","series-title":"Single-center Experience Suggests Donor Lymphocyte Infusion May Promote Long-Term Survival in Children with High-Risk Acute Lymphoblastic Leukemia","author":"Liberio","year":"2019"},{"key":"10.1016\/j.canlet.2022.215721_bib51","series-title":"A Multicentre UK Study of GVHD Following DLI: Rates of GVHD Are High but Mortality from GVHD Is Infrequent","author":"Scarisbrick","year":"2015"},{"key":"10.1016\/j.canlet.2022.215721_bib52","series-title":"Treatment of Relapsed AML and MDS after Allogeneic Stem Cell Transplantation with Decitabine and DLI\u2014A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group","author":"Schroeder","year":"2018"},{"key":"10.1016\/j.canlet.2022.215721_bib53","doi-asserted-by":"crossref","unstructured":"Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn J-Y, Frangoul HA, et al. Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation [Internet]. 2015 [cited 2021 Aug 1];21:151\u20138. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1083879114006314.","DOI":"10.1016\/j.bbmt.2014.10.006"},{"key":"10.1016\/j.canlet.2022.215721_bib54","author":"Anwer"},{"key":"10.1016\/j.canlet.2022.215721_bib55","author":"Zhang"},{"key":"10.1016\/j.canlet.2022.215721_bib56","author":"Zhang"},{"key":"10.1016\/j.canlet.2022.215721_bib57","first-page":"430","volume":"vol. 573","author":"Aghajanian","year":"2019"},{"key":"10.1016\/j.canlet.2022.215721_bib58","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","author":"Mougiakakos","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215721_bib59","doi-asserted-by":"crossref","DOI":"10.1172\/JCI135754","article-title":"Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease","author":"Shrestha","year":"2020"},{"key":"10.1016\/j.canlet.2022.215721_bib60","series-title":"Abstract 2310: Functional Demonstration of CD19 Chimeric Antigen Receptor (CAR) Engineered Epstein-Barr Virus (EBV) Specific T Cells: an Off-The-Shelf","author":"Shen","year":"2019"},{"key":"10.1016\/j.canlet.2022.215721_bib61","author":"Rust"},{"key":"10.1016\/j.canlet.2022.215721_bib62","doi-asserted-by":"crossref","unstructured":"Liu B, Zhang W, Zhang H. Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir. Current Opinion in Virology [Internet]. 2019 [cited 2021 Aug 2];38:21\u201330. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1879625719300203.","DOI":"10.1016\/j.coviro.2019.04.004"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522002051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522002051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:06:55Z","timestamp":1759594015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383522002051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":58,"alternative-id":["S0304383522002051"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215721","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unity brings strength: Combination of CAR-T cell therapy and HSCT","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"215721"}}